Latest Breaking News On - Ulrich krasilnikoff - Page 1 : comparemela.com

Curasight publishes information memorandum in connection with forthcoming rights issue

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/  Curasight A/S Curasight or the Company – has today resolved on a new issue of shares with preferential rights for the Company s existing.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

/PRNewswire/ Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic.

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in.

Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)

Preclinical studies show uTREAT® effective in treating non-small cell lung cancer Data follows recent announcement of positive preclinical results within glioblastoma and supports hypothesis.